8-K: Moleculin Biotech Announces Positive Preliminary Annamycin Trial Data and Outlines 2024 Milestones

Moleculin Biotech reports encouraging preliminary data from its Annamycin clinical trials and sets expectations for multiple data readouts and a transition to pivotal Phase 2B/3 studies in 2024.

Summary

• Moleculin Biotech has released preliminary data from its Annamycin clinical trials, showing positive results in both AML and STS lung metastases.
• The MB-106 AML trial reached 67% recruitment and showed a 40% complete response (CR) rate and a 47% CR/CRi rate in the intent-to-treat group (N=15).
• The dosed per protocol group in the AML trial had a 46% CR rate and a 54% CR/CRi rate (N=13).
• The first 1st line AML subject treated in the MB-106 trial achieved a complete response.
• No relapses have been reported in the MB-106 trial to date.
• The MB-107 STS lung metastases trial showed a median overall survival of 11 months for heavily pre-treated subjects (N=15) in the Phase 1B portion.
• 100% of Annamycin subjects across multiple studies (N=62) showed no signs of cardiotoxicity.
• The company expects to complete enrollment of 2nd line AML patients by the end of March 2024.
• Moleculin plans to initiate a pivotal Phase 2B/3 clinical trial for AML before the end of 2024.
• The company's cash runway has been extended into the fourth quarter of 2024 due to recent financing.

Sentiment

Score: 8

Explanation: The document presents positive preliminary clinical data, clear milestones, and a strong focus on moving towards pivotal trials. The absence of cardiotoxicity is a major positive. The company has also extended its cash runway. There are some risks and uncertainties, but the overall tone is optimistic.

Positives

• The preliminary data from the Annamycin clinical trials are encouraging.
• The AML trial shows a high complete response rate.
• The STS lung metastases trial demonstrates promising overall survival.
• There is no evidence of cardiotoxicity in any Annamycin subjects.
• The company is progressing towards pivotal Phase 2B/3 clinical trials.
• The company has secured funding to extend its cash runway into the fourth quarter of 2024.

Negatives

• Two subjects in the AML trial experienced adverse events, one due to an allergic reaction to Annamycin and the other to cytarabine.
• Most subjects experienced myelosuppression, febrile neutropenia and/or thrombocytopenia, which are common adverse events with other anthracyclines.

Risks

• The preliminary data is subject to change.
• The company's ability to replicate preclinical animal model results in human trials is uncertain.
• The timing of investigator-sponsored and externally funded clinical trials is outside the company's control.
• The company is dependent on regulatory approvals for its drug candidates.
• The company is subject to risks and uncertainties as detailed in their SEC filings.

Future Outlook

The company anticipates multiple data readouts in 2024 and plans to transition to pivotal Phase 2B/3 clinical trials by the end of the year. They also expect to initiate a pivotal program for AML and a 1st line STS study in late 2024 into 1H 2025.

Management Comments

• Walter Klemp, Chairman and CEO, stated that the company is well-positioned to continue building upon encouraging preliminary clinical data and transition to pivotal Phase 2B/3 clinical trials by year-end 2024.
• Mr. Klemp believes that Annamycin should be positioned as a 2nd line therapy for AML and enable a clear majority of patients to benefit from anthracyclines.
• Mr. Klemp noted that the company's progress is accelerating and that the results are even stronger with an increase in evaluable patients.

Industry Context

This announcement is significant as it highlights the potential of Annamycin as a next-generation anthracycline with reduced cardiotoxicity, addressing a major limitation of current AML and STS treatments. The company's focus on pivotal trials and accelerated approval pathways aligns with the industry's push for faster drug development and access to innovative therapies.

Comparison to Industry Standards

• The reported 40% CR rate and 47% CR/CRi rate in the intent-to-treat group for AML is competitive with other second-line AML therapies, though direct comparisons are difficult without full trial data.
• The 11-month median overall survival in heavily pre-treated STS lung metastases patients is promising, especially considering the limited treatment options for this patient population. For example, the median overall survival for patients with advanced soft tissue sarcoma treated with doxorubicin is around 12 months.
• The absence of cardiotoxicity in all Annamycin subjects is a significant advantage compared to traditional anthracyclines, which are known for their cardiotoxic side effects. For example, doxorubicin has a known risk of cardiotoxicity, which can limit its use.

Stakeholder Impact

• Shareholders will be encouraged by the positive clinical trial data and the company's progress towards pivotal trials.
• Patients with AML and STS lung metastases may benefit from the development of Annamycin.
• Employees will be motivated by the company's progress and the potential for future success.
• Collaborators will be encouraged by the positive results and the company's commitment to advancing its drug candidates.

Next Steps

• The company will conduct an in-depth data review and presentation of topline data on the MB-106 clinical trial in the first half of 2024.
• The company will hold an End of Phase 2 (EOP2) Meeting with the FDA and/or its European equivalent in the first half of 2024.
• The company will identify the next phase of development/pivotal program by mid-2024.
• The company will initiate a pivotal program in late 2024 into 1H 2025.
• The company will have a final MB-107 data readout in the second half of 2024.
• The company will initiate a 1st line STS study with an investigator-initiated trial in late 2024 into 1H 2025.
• The company expects to finalize agreements with Northwestern University for an investigator-initiated and funded trial in early 2024.
• The company will report topline results from an investigator-initiated Phase 1 study in pediatric brain tumors.
• The company will announce results of formulation efforts for intravenous delivery.
• The company expects the commencement of an externally funded investigator-initiated adult clinical trial to be announced in 1H 2024.
• The company is seeking an investigator-initiated pediatric cancer clinical trial in 2H 2024.
• The company will report preliminary findings of National Institutes of Health (NIH) funded animal testing of WP1096 in the Tacaribe Arenavirus.
• The company will identify investigators interested in initiating a clinical trial to study the safety, pharmacokinetics, and efficacy of oral WP1122 in adult patients with GBM.

Key Dates

Keywords

Annamycin, AML, STS, clinical trials, cancer, oncology, biotech, pharmaceutical, MB-106, MB-107, cardiotoxicity, pivotal study, FDA, WP1066, WP1122